RedHill Biopharma rises as COVID-19 drug works against Delta variant
26/08/2021 12:02
** U.S.-listed shares of Israel-based drug developer
RDHL.O jump 17% to $8.40 premarket- set to open at a more than
5-mth high if gains hold
** Says early results of a new preclinical study show its
oral COVID-19 drug candidate, opaganib, inhibits the Delta
variant first found in India urn:newsml:reuters.com:*:nPnz17MFa
** Previous studies have shown the drug inhibits the Alpha,
Beta and Gamma variants and opaganib is expected to be effective
against other emerging variants- Co
** Opaganib is currently being evaluated as a treatment for
COVID-19 pneumonia in a global mid-to-late stage study, which
has completed patient treatment and follow-up
** RDHL down 11.1% YTD up to last close
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))